WO2009131384A3 - Pharmaceutical composition for preventing and treating malaria, containing compounds that inhibit plasmepsin ii activity, and method of treating malaria using the same - Google Patents

Pharmaceutical composition for preventing and treating malaria, containing compounds that inhibit plasmepsin ii activity, and method of treating malaria using the same Download PDF

Info

Publication number
WO2009131384A3
WO2009131384A3 PCT/KR2009/002114 KR2009002114W WO2009131384A3 WO 2009131384 A3 WO2009131384 A3 WO 2009131384A3 KR 2009002114 W KR2009002114 W KR 2009002114W WO 2009131384 A3 WO2009131384 A3 WO 2009131384A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
treating malaria
malaria
preventing
plasmepsin
Prior art date
Application number
PCT/KR2009/002114
Other languages
French (fr)
Other versions
WO2009131384A2 (en
Inventor
Do-Man Kim
Hee-Kyoung Kang
Do-Won Kim
Giulio Rastelli
Ana-Lucia Da Costa
Vinod Kasam
Vincent Breton
Original Assignee
Industry Foundation Of Chonnam National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Foundation Of Chonnam National University filed Critical Industry Foundation Of Chonnam National University
Publication of WO2009131384A2 publication Critical patent/WO2009131384A2/en
Publication of WO2009131384A3 publication Critical patent/WO2009131384A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition containing a compound that binds to active sites of plasmepsin II to inhibit activity, and a method of preventing and treating malaria, including administering an effective dose of the pharmaceutical composition to a mammal. The pharmaceutical composition of the invention contains at least one compound selected from the group consisting of an N- alkoxyamidine derivative, a guanidine derivative, an amide derivative, a urea or thiourea derivative, and N- (2-{[3-(l,3 -benzodioxol- 5 -yl) - 3 -oxo- 1 -propene- 1 -yl] amino } phenyl)-4-nitrobenzene sul¬ fonamide. The compound contained in the pharmaceutical composition is used to prevent and treat malaria since it binds to active sites of plasmepsin II to inhibit activity. The compound is effective to malaria that is resistant to existing anti-malarial drugs.
PCT/KR2009/002114 2008-04-22 2009-04-22 Pharmaceutical composition for preventing and treating malaria, containing compounds that inhibit plasmepsin ii activity, and method of treating malaria using the same WO2009131384A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080037148A KR100982661B1 (en) 2008-04-22 2008-04-22 Pharmaceutical composition for the prevention and treatment of malaria containing a compound that inhibits plasmincin II activity as an active ingredient and a method for treating malaria using the same
KR10-2008-0037148 2008-04-22

Publications (2)

Publication Number Publication Date
WO2009131384A2 WO2009131384A2 (en) 2009-10-29
WO2009131384A3 true WO2009131384A3 (en) 2010-02-04

Family

ID=41217271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002114 WO2009131384A2 (en) 2008-04-22 2009-04-22 Pharmaceutical composition for preventing and treating malaria, containing compounds that inhibit plasmepsin ii activity, and method of treating malaria using the same

Country Status (2)

Country Link
KR (1) KR100982661B1 (en)
WO (1) WO2009131384A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139532B2 (en) 2010-12-08 2015-09-22 Lycera Corporation Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
MX2013006398A (en) 2010-12-08 2013-12-02 Lycera Corp Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof.
WO2012084999A1 (en) * 2010-12-21 2012-06-28 Universite De Strasbourg Prokineticin 1 receptor agonists and their uses
EP2468279A1 (en) * 2010-12-21 2012-06-27 Université de Strasbourg Prokineticin 1 receptor agonists and their uses
EP2866796A4 (en) 2012-06-08 2015-11-25 Lycera Corp Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2013185048A2 (en) 2012-06-08 2013-12-12 Lycera Corporation Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2013185046A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Saturated acyl guanid1ne for inhibition of f1f0-atpase
JP2016539993A (en) 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ N-substituted pyrazolylguanidine F1F0-ATPase inhibitor and therapeutic use thereof
EP3080089B1 (en) 2013-12-10 2019-05-08 Lycera Corporation Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof
JP2016539983A (en) 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Alkylpyrazolylguanidine F1F0-ATPase inhibitor and therapeutic use thereof
EP4298089A1 (en) * 2021-02-26 2024-01-03 Brown University Compositions and methods for the treatment of plasmodium falciparum malaria

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941825A (en) * 1973-07-27 1976-03-02 American Cyanamid Company Substituted aminobenzylideneamino guanidine compounds
KR20020010709A (en) * 1999-06-16 2002-02-04 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 IL-8 Receptor Antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941825A (en) * 1973-07-27 1976-03-02 American Cyanamid Company Substituted aminobenzylideneamino guanidine compounds
KR20020010709A (en) * 1999-06-16 2002-02-04 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 IL-8 Receptor Antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KASAM ET AL.: "Design of new plasmepsin inhibitors A virtual high throughput screening approach on the EGEE grid", J CHEM INF MODEL, vol. 47, 2007, pages 1818 - 1828 *

Also Published As

Publication number Publication date
WO2009131384A2 (en) 2009-10-29
KR20090111502A (en) 2009-10-27
KR100982661B1 (en) 2010-09-17

Similar Documents

Publication Publication Date Title
WO2009131384A3 (en) Pharmaceutical composition for preventing and treating malaria, containing compounds that inhibit plasmepsin ii activity, and method of treating malaria using the same
BRPI0909768A2 (en) compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by activation of b3-adrenoceptor, and use of a compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by b3-adrenoceptor. b3-adrenoceptor activation, and use of a compound
BRPI0610514A2 (en) compound, pharmaceutical composition, and method of treating a disorder
BR112014015568A2 (en) phenyl carbamate compounds for use in the prevention or treatment of epilepsy
BRPI0718587A2 (en) USE OF A COMPOUND, COMPOUNDS, METHOD OF TREATING OR PREVENTING DISEASES, PROCESSES FOR THE PREPARATION OF COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
BRPI0917458A2 (en) compound, method of treating disease and conditions, pharmaceutical composition, method for treating or preventing disease, and use of a compound
WO2007112000A3 (en) Treatment of pain
TN2010000019A1 (en) Solid preparation comprising alogliptin and metformin hydrochloride
WO2010021680A3 (en) Inhibitors of beta-secretase
EA200601746A1 (en) APPLICATION OF ROTIGOTINE FOR THE TREATMENT AND PREVENTION OF THE PARKINSONISM-PLUS SYNDROME
BRPI0607545A2 (en) compound, use of a compound of formula I or a pharmaceutically acceptable salt thereof, and pharmaceutical composition
BR0315580A (en) Methylene Urea Derivatives
CA2449999A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
EA200971041A1 (en) NEW PEPTIDE HEPATITIS C VIRUS REPLICATION INHIBITORS
BRPI1013394A2 (en) "compound, pharmaceutical composition, use of the compound, and method for treating a hepatitis c virus infected patient."
PE20061025A1 (en) ANILIDES OF PYRAZOLCARBOXYL ACID
BRPI0907976A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease
BRPI0713755A8 (en) compound or a salt or solvate thereof, use of the compound or a salt or salvate thereof, pharmaceutical composition, and process for the preparation of a compound or a salt or solvate thereof
BRPI0908124A2 (en) Compound, glucokinase activator, pharmaceutical composition, use of a pharmaceutically acceptable salt or compound thereof, and methods of activating glucokinase, and to treat and / or prevent a disease.
BRPI0607775A2 (en) conjugate, pharmaceutical composition, use of a compound, and method for treating or preventing disease
BRPI0914371A2 (en) "compound, pharmaceutical composition, use of a compound, method of treating an individual, and combination product"
BRPI0607748A2 (en) compound, pharmaceutical composition, and method of treating a disorder
CL2007003587A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE TO TREAT OR PREVENT INFECTION OF HEPATITIS C.
CL2007000918A1 (en) COMPOUNDS DERIVED FROM ENFUMAFUNGINA, INHIBITORS OF (1,3) -BETA-D-GLUCANOSINTETASE; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT A FUNGICAL INFECTION.
CL2007003120A1 (en) USE OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF COMPOUNDS DERIVED FROM SUBSTITUTED CARBAMIC ACID AND ANOTHER ACTIVE AGENT, FOR THE TREATMENT OF DEPRESSION.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09735108

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09735108

Country of ref document: EP

Kind code of ref document: A2